13th Edition of International Conference on Neurology and Brain Disorders
October 19-21, 2026
Schizophrenia
Schizophrenia is a chronic, severe, and disabling brain disorder that has affected people throughout history. It is characterized by hallucinations, delusions, and disorganized thinking and behavior. Symptoms may include talking to oneself, hearing voices, paranoia, and poor emotional control. People with schizophrenia often experience difficulties with daily activities, including work, school, and relationships. The cause of schizophrenia is unknown, but it is thought to involve a combination of environmental and genetic factors. It is believed to be related to a disruption in how the brain processes dopamine, a neurotransmitter involved in understanding and interpreting reality. Schizophrenia is also linked to abnormalities in brain structure and function, which can be seen in brain imaging scans, such as MRI. Treatment for schizophrenia is focused on controlling symptoms and improving quality of life. Common medications used for treatment include antipsychotic drugs like clozapine, risperidone, and olanzapine. These help to reduce hallucinations, delusions, and other symptoms. Therapy can also be used to help people cope with the social, emotional, and cognitive challenges of their disorder. Additionally, it is important for individuals to take an active role in managing their symptoms and recovery. Schizophrenia can be a difficult disorder to manage and treatment can often involve a multidisciplinary approach. It is important to remember that people with schizophrenia can still lead meaningful and productive lives with the proper support and treatment.
Ken Ware
NeuroPhysics Therapy Institute and Research Centre, Australia
Yong Xiao Wang
Albany Medical College, United States
Joe Sam Robinson
Mercer University, United States
Daniel Curry
Texas Children’s Hospital, United States
Steven Benvenisti
Davis, Saperstein Salomon, PC, United States
Andrzej Stanislaw Cieplak
Independent researcher, United States
Younok Dumortier Shin
OnusBio, United StatesSubmit your abstract Today
Title : Atypical presentation of Juvenile myoclonic epilepsy in a 16-year-old female: A case report
George Diaz, Memorial Healthcare Systems, United States
Title : Triple-network dysfunction, ME/CFS, and the NeuroPhysics Treatment Process “A dynamical systems perspective on psychophysical organization and environmental interaction”
Ken Ware, NeuroPhysics Therapy Institute and Research Centre, Australia
Title : Beyond plaques: 10-nanometer-scale pathoconnectomics of Alzheimer’s disease
Ons M Saad, Panluminate Inc., United States
Title : Results from the global phase 3 trial (IB1001-303) evaluating levacetylleucine in children and adults with ataxia-telangiectasia
Chidinma Ejim, IntraBio, United States
Title : A phase 3, multinational, randomized, placebo-controlled, double-blind, crossover trial (IB1001-304) evaluating levacetylleucine in CACNA1A
Chidinma Ejim, IntraBio, United States
Title : Clinical and molecular phenotype of PTRHD1-associated juvenile parkinsonism
Bhavan A Modi, Barrow Neurological Institute at Phoenix Children's, United States